Co-Authors
This is a "connection" page, showing publications co-authored by Otavio Berwanger and Fernando Zampieri.
Connection Strength
0.693
-
Hydroxychloroquine with or without Azithromycin in Covid-19. Reply. N Engl J Med. 2021 01 14; 384(2):191.
Score: 0.229
-
Study protocol for the Balanced Solution versus Saline in Intensive Care Study (BaSICS): a factorial randomised trial. Crit Care Resusc. 2017 Jun; 19(2):175-182.
Score: 0.180
-
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 01 20; 372:n84.
Score: 0.058
-
Quality of life and long-term outcomes after hospitalization for COVID-19: Protocol for a prospective cohort study (Coalition VII). Rev Bras Ter Intensiva. 2021 Jan-Mar; 33(1):31-37.
Score: 0.058
-
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 10 06; 324(13):1307-1316.
Score: 0.057
-
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020 10 03; 396(10256):959-967.
Score: 0.056
-
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 11 19; 383(21):2041-2052.
Score: 0.056